高负担HIV/TB国家结核预防治疗试验中QFT-Plus结果的动态变化
该研究在埃塞俄比亚、莫桑比克和南非三个高TB/HIV负担国家纳入HIV感染者,随机接受3HP、每年重复3HP(p3HP)或6H方案,在基线、12月和24月进行QFT-Plus检测。结果显示QFT-Plus转换和复转频繁,且不因预防治疗方案或是否接受第二疗程而异;基线QFT-Plus阳性者研究期间发生TB风险更高。
要点
- HIV感染者中QFT-Plus转换和复转常见,不受TPT方案影响。
- 基线QFT-Plus阳性者TB风险增高(aHR 1.66)。
- 高传播场景下连续IGRA结果解读复杂。
核心结论
- HIV感染者中QFT-Plus转换和复转频繁,且不因TPT方案或是否接受第二疗程而异。
- 基线QFT-Plus阳性者研究期间发生TB风险更高(aHR 1.66,95%CI 1.41-1.89,P=.034)。
研究设计与样本
- 在埃塞俄比亚、莫桑比克和南非三个高TB/HIV负担国家开展的临床试验。
- HIV感染者随机接受3HP、p3HP(每年一次共2年)或6H方案。
- 在基线、12月和24月进行QFT-Plus检测,分析定量和定性结果及转换/复转。
主要发现
- 基线至12月,13.0%(196/1502)参与者发生转换,3HP组13.1%与6H组12.9%无差异。
- 12月至24月,p3HP组转换率4.0%,未接受第二疗程的3HP组为9.4%(P=.110)。
- 总体复转率19.0%(178/935),各治疗组和时间点相似。
临床怎么用
- HIV感染者连续QFT-Plus结果应谨慎解读,转换不一定代表新感染。
- 基线QFT-Plus阳性提示TB风险增高,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report the longitudinal analysis of QuantiFERON-TB Gold Plus (QFT-Plus) results from a clinical trial conducted in 3 countries with a high tuberculosis (TB)/human immunodeficiency virus (HIV) burden, comparing 3 different TB preventive treatment (TPT) regimens in people with HIV (PWH). METHODS: PWH were enrolled in Ethiopia, Mozambique, and South Africa and randomized to (i) 1 course of weekly rifapentine-isoniazid for 3 months (3HP), (ii) weekly rifapentine-isoniazid for 3 months given annually for 2 years (p3HP), or (iii) daily isoniazid for 6 months (6H). QFT-Plus testing was performed at baseline, month 12, and month 24. Quantitative and qualitative results, and serial changes (conversions and reversions) were assessed. RESULTS: From baseline to month 12, 13.0% (196/1502) of participants converted, with no differences between 3HP (13.1%) and 6H (12.9%). From month 12 to month 24, conversion occurred in 4.0% of participants receiving a second course of 3HP (p3HP arm), and in 9.4% of those not receiving a second course (3HP) (P = .110). Overall reversions occurred in 19.0% (178/935) of participants. Reversion rates were similar across study arms and timepoints. The risk of developing TB during the study period was higher among individuals who were QFT-Plus positive at baseline (adjusted hazard ratio, 1.66 [95% confidence interval, 1.41-1.89], P = .034). CONCLUSIONS: QFT-Plus conversions and reversions occurred frequently in PWH and did not differ by TPT regimen or between those who did and did not receive a second course of TPT. The high rate of QFT positivity, along with the large proportion of conversions despite TPT, highlights the complexity of interpreting serial interferon-gamma release assay results in PWH in high-transmission scenarios.
引用
- Saavedra-Cervera B, Nguenha D, Chihota V, et al. Dynamics of QuantiFERON-TB Gold Plus Results in a Large TB Preventive Treatment Trial Across 3 High-Burden HIV/TB Countries. J Infect Dis. 2026. PMID: 41843759. doi:10.1093/infdis/jiag165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。